Biocircuits
This article was originally published in The Gray Sheet
Executive Summary
Ceases business operations effective May 18 because of an inability to "secure additional financing or to arrange a sale or merger" and because the company "has insufficient funds to continue operations," the Sunnyvale, California firm reports in a May 19 release. Biocircuits, which launched the IOS point of care immunodiagnostic system in 1996 ("The Gray Sheet" Dec. 11, 1995, I&W-8), netted about $5.1 mil. from a private placement last July and had inked a letter of intent agreement granting Becton Dickinson manufacturing and exclusive worldwide distribution rights to the IOS system and marketing rights to all existing and future test cartridges ("The Gray Sheet" July 14, 1997, p. 13)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.